Actavis, which is buying Botox-maker Allergan for $66 billion in one of the biggest acquisitions announced so far this year, plans to stay committed to developing new products.
Pediatricians are advocating for safe infant sleep practices, concerned by too many sudden unexplained infant deaths in recent years and a rise in bed-sharing among families with infants. According to UMass Medical School ...
In a win for Valeant and Pershing Square, a federal judge has decided that they can vote in takeover target Allergan's upcoming shareholder meeting.
The drugmaker AbbVie surprised Wall Street on Friday with a third-quarter performance that turned out much better than expected and a new 2014 forecast that also extends well beyond what analysts predict.
The Canadian drugmaker Valeant said it would be willing to raise its takeover bid for Allergan by almost 12 percent, which would mean $200 or more per share for the maker of Botox.